Product Description
a potent oral small molecule galectin-3 inhibitor
Mechanisms of Action: GAL3 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galecto Biotech
Company Location: BOSTON MA 02109
Company CEO: Hans T. Schambye
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Netherlands, Poland, Spain, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Galecto Biotech announced they will present P2 Head and Neck Cancer|Melanoma results in YE25 for GB-1211
Highest Development Phases
Phase 2: Head and Neck Cancer|Melanoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT05913388 | P2 |
Recruiting |
Head and Neck Cancer|Melanoma|Squamous Cell Carcinoma |
2028-02-01 |
12% |
2024-03-29 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| GALLANT-1 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-08-01 |
2025-05-02 |
Treatments |
|
| GALBA-1 | P1 |
Completed |
Healthy Volunteers |
2023-04-10 |
69% |
2023-09-02 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| GALLANT-1 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2025-02-16 |
2025-05-06 |
Treatments|Trial Status |
|
| GALLANT-1 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2024-05-30 |
39% |
2024-04-13 |
Primary Endpoints |